A pivotal role for Mcl-1 in Bortezomib-induced apoptosisPODAR, K; GOUILL, S. L; ANDERSON, K. C et al.Oncogene (Basingstoke). 2008, Vol 27, Num 6, pp 721-731, issn 0950-9232, 11 p.Article

Gα_12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulationYOON MEE YANG; LEE, Sanghwan; CHANG WON NAM et al.Carcinogenesis (New York. Print). 2010, Vol 31, Num 7, pp 1230-1237, issn 0143-3334, 8 p.Article

The role of proteasome inhibitors in solid tumors : Proteasome inhibitionPARK, David J; LENZ, Heinz-Josef.Annals of medicine (Helsinki). 2004, Vol 36, Num 4, pp 296-303, issn 0785-3890, 8 p.Article

Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade)ARPINATI, M; CHIRUMBOLO, G; NICOLINI, B et al.Bone marrow transplantation (Basingstoke). 2009, Vol 43, Num 3, pp 253-259, issn 0268-3369, 7 p.Article

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapyDICK, Lawrence R; FLEMING, Paul E.Drug discovery today. 2010, Vol 15, Num 5-6, pp 243-249, issn 1359-6446, 7 p.Article

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal diseaseWECHALEKAR, Ashutosh D; LACHMANN, Helen J; OFFER, Mark et al.Haematologica (Roma). 2008, Vol 93, Num 2, pp 295-298, issn 0390-6078, 4 p.Article

Incorporating bortezomib into upfront treatment for multiple myeloma : early results of total therapy 3BARLOGIE, Bart; ANAISSIE, Elias; BOLEJACK, Vanessa et al.British journal of haematology. 2007, Vol 138, Num 2, pp 176-185, issn 0007-1048, 10 p.Article

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment StrategyWRIGHT, John J.Clinical cancer research (Print). 2010, Vol 16, Num 16, pp 4094-4104, issn 1078-0432, 11 p.Article

Can Tumor Growth Be Further Inhibited by Combining Drugs Such as Bortezomib with Image-guided Interventional Oncologic Procedures?NAHUM GOLDBERG, S.Radiology. 2008, Vol 248, Num 2, pp 323-325, issn 0033-8419, 3 p.Article

Bortezomib: clinical profile in lymphoproliferative malignanciesO'CONNOR, Owen A.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 6, pp 18-24, issn 1359-6349, 7 p.Conference Paper

Bortezomib in multiple myeloma: Treatment approach and outcomesHAROUSSEAU, Jean-Luc.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 6, pp 12-17, issn 1359-6349, 6 p.Conference Paper

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse EventsARASTU-KAPUR, Shirin; ANDERL, Janet L; KIRK, Christopher J et al.Clinical cancer research (Print). 2011, Vol 17, Num 9, pp 2734-2743, issn 1078-0432, 10 p.Article

Approval summary for bortezomib for injection in the treatment of multiple myelomaBROSS, Peter F; KANE, Robert; LEIGHTON, John et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 3954-3964, issn 1078-0432, 11 p., 1Article

Velcade® (bortezomib) dans le traitement du myélome multiple : résultats des essais cliniquesFACON, Thierry.Hématologie (Montrouge). 2004, Vol 10, pp 9-12, issn 1264-7527, 4 p., NS3Conference Paper

Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction : Targeting the Ubiquitin-Proteasome Pathway - Current Perspectives and Future DirectionsBIYIN CAO; JIE LI; XINLIANG MAO et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 18, pp 3190-3200, issn 1381-6128, 11 p.Article

The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of BortezomibCVEK, Boris; DVORAK, Zdenek.Current pharmaceutical design (Print). 2011, Vol 17, Num 15, pp 1483-1499, issn 1381-6128, 17 p.Article

Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytesPISCIANZ, Elisa; CUZZONI, Eva; DE IUDICIBUS, Sara et al.International immunopharmacology (Print). 2011, Vol 11, Num 12, pp 2242-2245, issn 1567-5769, 4 p.Article

Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cellsALBERO, M. P; VAQUER, J. M; ANDREU, E. J et al.Oncogene (Basingstoke). 2010, Vol 29, Num 22, pp 3276-3286, issn 0950-9232, 11 p.Article

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myelomaNOBORIO-HATANO, K; KIKUCHI, J; OZAKI, K et al.Oncogene (Basingstoke). 2009, Vol 28, Num 2, pp 231-242, issn 0950-9232, 12 p.Article

Characterization of the ubiquitin―proteasome system in bortezomib-adapted cellsRÜCKRICH, T; KRAUS, M; GOGEL, J et al.Leukemia. 2009, Vol 23, Num 6, pp 1098-1105, issn 0887-6924, 8 p.Article

A multicenter retrospective analysis of adverse events in korean patients using bortezomib for multiple myelomaBANG, Soo-Mee; JAE HOON LEE; KIM, Kihyun et al.International journal of hematology. 2006, Vol 83, Num 4, pp 309-313, issn 0925-5710, 5 p.Article

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administrationTERPOS, Evangelos; POLITOU, Marianna; RAHEMTULLA, Amin et al.Journal of cancer research and clinical oncology. 2004, Vol 130, Num 10, pp 623-625, issn 0171-5216, 3 p.Article

ASTROCYTES, BUT NOT MICROGLIA, ARE ACTIVATED IN OXALIPLATIN AND BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY IN THE RATROBINSON, C. R; ZHANG, H; DOUGHERTY, P. M et al.Neuroscience. 2014, Vol 274, pp 308-317, issn 0306-4522, 10 p.Article

Neurotoxicity induced by antineoplastic proteasome inhibitorsALE, Albert; BRUNA, Jordi; NAVARRO, Xavier et al.Neurotoxicology (Park Forest South). 2014, Vol 43, pp 28-35, issn 0161-813X, 8 p.Conference Paper

Plasma cell leukemia: advantages of treatment with bortezomibFRAIMOUT, N; KADOUCH, B; TICCHIONI, M et al.Targeted oncology. 2008, Vol 3, Num 4, pp 265-267, issn 1776-2596, 3 p.Article